169 documents

Read All
21:45 , Apr 26, 2018 |  BC Extra  |  Company News

Shire reports first sales after neuroscience, rare disease split

In its 1Q18 earnings, Shire plc (LSE:SHP; NASDAQ:SHPG) released its first figures since splitting its neuroscience and rare disease businesses into two divisions (see BioCentury Extra, Jan. 9) . For the quarter, Shire's rare disease...
Read More
01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global...
Read More
21:12 , Jan 5, 2018 |  BC Week In Review  |  Company News

Allergan cutting jobs ahead of Restasis competition

Allergan plc (NYSE:AGN) announced details Thursday of a plan to reduce costs as it braces for potential generic competition to its blockbuster dry eye drug Restasis cyclosporine this year. The company will cut over 1,000...
Read More
23:00 , Jan 4, 2018 |  BC Extra  |  Company News

Allergan cutting jobs ahead of Restasis competition

Allergan plc (NYSE:AGN) announced details Thursday of a plan to reduce costs as it braces for potential generic competition to its blockbuster dry eye drug Restasis cyclosporine this year. The company will cut over 1,000...
Read More
20:51 , Jun 16, 2017 |  BC Week In Review  |  Company News

GeneriCo wins IPR for Apriso

In a May...
Read More
07:00 , Oct 10, 2016 |  BC Week In Review  |  Company News

Cosmo, Shire autoimmune news

The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTO) upheld the validity of the only Orange Book-listed patent for ulcerative colitis drug Lialda mesalamine from Shire. PTAB evaluated an inter...
Read More
07:00 , Oct 6, 2016 |  BC Extra  |  Company News

PTAB upholds Lialda patent's validity

The Patent Trial and Appeal Board of the U.S. Patent and Trademark Office upheld the validity of the only Orange Book-listed patent for ulcerative colitis drug Lialda mesalamine from Shire plc (LSE:SHP; NASDAQ:SHPG). PTAB evaluated...
Read More
07:00 , Apr 25, 2016 |  BioCentury  |  Politics, Policy & Law

SCOTUS to the rescue?

The U.S. Supreme Court will hear arguments on Monday in a case that could either overturn or reinforce policies that unfairly tilt the inter partes review system against patent holders, according to life sciences companies....
Read More
07:00 , Apr 4, 2016 |  BC Week In Review  |  Company News

Allergan, Shire autoimmune news

The U.S. District Court for the District of Southern Florida upheld a patent protecting Shire’s ulcerative colitis drug Lialda mesalamine and granted an injunction blocking approval and sale of a generic form of the drug...
Read More
01:31 , Mar 30, 2016 |  BC Extra  |  Company News

District court again sides with Shire in Lialda dispute

The U.S. District Court of Southern Florida upheld a patent protecting ulcerative colitis drug Lialda mesalamine from Shire plc (LSE:SHP; NASDAQ:SHPG) and granted an injunction blocking approval and sale of a generic form of the...
Read More